SLU-PP-332
SLU-PP-332 is a small-molecule pan-ERR agonist with mouse endurance and metabolic results, ex vivo human myoblast work, no oral bioavailability, and no human administration study.
tier C · weight loss · 0 human administration studies
verdict
SLU-PP-332 activates an oxidative exercise-response program and improved specific outcomes in mice. It has not been administered to people in the located record.
whether it is a peptide: No. It is a synthetic small molecule and a pan-agonist at ERR alpha, beta, and gamma.
what the mouse data show: Injected mouse studies reported endurance, oxidative-muscle, metabolic, heart-failure, and kidney findings. Those results remain preclinical.
what the human-derived study means: The compound was applied to primary myoblast cultures grown from biopsies. It was not administered to the women who supplied the tissue.
The dedicated 2026 successor paper states that SLU-PP-332 lacks oral bioavailability.
why C-tier
C-tier reflects direct and repeated preclinical findings with no human administration evidence.
the core tension
The mouse mechanism and outcomes are real research findings. Human administration, exposure, safety, and efficacy remain unanswered.
what it is
SLU-PP-332 is a synthetic acylhydrazone small molecule, formula C18H14N2O2, developed as a pan-agonist of estrogen-related receptors ERR alpha, beta, and gamma. It is not a peptide and does not activate classical estrogen receptors in the foundational work.
what it does
ERR activation changed oxidative and mitochondrial gene programs in mouse skeletal muscle. Sedentary mice ran longer and farther, and separate mouse studies reported metabolic, cardiac, and kidney findings.
origin
The Burris research group developed SLU-PP-332 as a chemical probe. A later paper built the chemically distinct SLU-PP-915 because 332 lacks oral bioavailability.
why researchers are interested
The mouse mechanism is legible and the endurance result is direct. The limits are equally direct: injection-only preclinical exposure, one originating research network, and no human administration.
does it work
In mice, 332 increased endurance and produced specific metabolic findings. No human efficacy or safety result exists in the reviewed record. The ex-vivo myoblast paper is cell culture, not a clinical trial.
key facts
- molecular formula: C18H14N2O2
- molecular weight: 290.32 g/mol
- amino acids: not a peptide
- half-life: no numeric human or animal concentration-time curve retained
- type: acylhydrazone small-molecule pan-ERR agonist
- CAS: 303760-60-3
- 0 human administration studies
- 50 mg/kg mouse metabolic-study dose, IP twice daily
- 28 days mouse metabolic-study duration
- none oral bioavailability
frequently asked questions
Is SLU-PP-332 a peptide?
No. It is an acylhydrazone small molecule and pan-ERR agonist.
Has SLU-PP-332 been studied in people?
No human administration study was located. One paper used cultured myoblasts derived from human biopsies, which is ex-vivo work.
What exact metabolic regimen was studied?
The cited metabolic mouse study used 50 mg/kg intraperitoneally twice daily for 28 days. That is not a human dose.
Is oral use supported?
No. The successor paper states that SLU-PP-332 lacks oral bioavailability.
related peptides
- SLU-PP-915: chemically distinct oral successor with its own mouse record
- 5-amino-1mq: different small-molecule target and animal evidence
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.
